| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study
|
Novello, S.
|
|
|
29 |
6 |
p. 1409-1416
|
artikel
|
| 2 |
Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors—Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO)
|
Rieger, C.T.
|
|
|
29 |
6 |
p. 1354-1365
|
artikel
|
| 3 |
ARTE and craft of bevacizumab in elderly patients with glioblastoma
|
Schiff, D.
|
|
|
29 |
6 |
p. 1346-1347
|
artikel
|
| 4 |
Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study
|
Gramatzki, D.
|
|
|
29 |
6 |
p. 1431-1436
|
artikel
|
| 5 |
Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial
|
Wirsching, H.-G.
|
|
|
29 |
6 |
p. 1423-1430
|
artikel
|
| 6 |
Complete response to CSF1R inhibitor in a translocation variant of teno-synovial giant cell tumor without genomic alteration of the CSF1 gene
|
Brahmi, M.
|
|
|
29 |
6 |
p. 1488-1489
|
artikel
|
| 7 |
Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer
|
Wang, H.
|
|
|
29 |
6 |
p. 1417-1422
|
artikel
|
| 8 |
Divergent adaptation in thyroid cancers
|
Sottoriva, A.
|
|
|
29 |
6 |
p. 1353
|
artikel
|
| 9 |
Early evolutionary divergence between papillary and anaplastic thyroid cancers
|
Capdevila, J.
|
|
|
29 |
6 |
p. 1454-1460
|
artikel
|
| 10 |
Editorial Board
|
|
|
|
29 |
6 |
p. ii-iii
|
artikel
|
| 11 |
Functional immune characterization of HIV-associated non-small-cell lung cancer
|
Pinato, D.J.
|
|
|
29 |
6 |
p. 1486-1488
|
artikel
|
| 12 |
Further evidence to support judicious use of antibiotics in patients with cancer
|
Luke, J.J.
|
|
|
29 |
6 |
p. 1349-1351
|
artikel
|
| 13 |
Is there a future for EGFR targeted agents in esophageal cancer?
|
Ilson, D.H.
|
|
|
29 |
6 |
p. 1343-1344
|
artikel
|
| 14 |
Latest clinical evidence and further development of PARP inhibitors in ovarian cancer
|
Mirza, M.R.
|
|
|
29 |
6 |
p. 1366-1376
|
artikel
|
| 15 |
Letter to the editor on ‘Body mass index and 20-specific cancers—re-analyses of dose-response meta-analyses of observational studies’
|
Markozannes, G.
|
|
|
29 |
6 |
p. 1490-1491
|
artikel
|
| 16 |
Methylation in cell-free DNA for early cancer detection
|
Fece de la Cruz, F.
|
|
|
29 |
6 |
p. 1351-1353
|
artikel
|
| 17 |
Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer
|
Derosa, L.
|
|
|
29 |
6 |
p. 1437-1444
|
artikel
|
| 18 |
Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08)
|
Ruhstaller, T.
|
|
|
29 |
6 |
p. 1386-1393
|
artikel
|
| 19 |
No association between circulating concentrations of vitamin D and risk of lung cancer: an analysis in 20 prospective studies in the Lung Cancer Cohort Consortium (LC3)
|
Muller, D.C.
|
|
|
29 |
6 |
p. 1468-1475
|
artikel
|
| 20 |
Oral bisphosphonate use and lung cancer incidence among postmenopausal women
|
Tao, M.H.
|
|
|
29 |
6 |
p. 1476-1485
|
artikel
|
| 21 |
Peri-operative therapy for operable gastroesophageal adenocarcinoma: past, present and future
|
Aggelis, V.
|
|
|
29 |
6 |
p. 1377-1385
|
artikel
|
| 22 |
Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma
|
Abou-Alfa, G.K.
|
|
|
29 |
6 |
p. 1402-1408
|
artikel
|
| 23 |
Purchasing silence
|
Tannock, I.F.
|
|
|
29 |
6 |
p. 1339-1340
|
artikel
|
| 24 |
Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer
|
Katakami, N.
|
|
|
29 |
6 |
p. 1461-1467
|
artikel
|
| 25 |
RET-fusions: a novel paradigm in colorectal cancer
|
Santos, C.
|
|
|
29 |
6 |
p. 1340-1343
|
artikel
|
| 26 |
RET fusions in a small subset of advanced colorectal cancers at risk of being neglected
|
Pietrantonio, F.
|
|
|
29 |
6 |
p. 1394-1401
|
artikel
|
| 27 |
Stringent vaccination of cancer patients: is it that important?
|
Weber, T.
|
|
|
29 |
6 |
p. 1348-1349
|
artikel
|
| 28 |
Table of Contents
|
|
|
|
29 |
6 |
p. iv-vi
|
artikel
|
| 29 |
Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification
|
Liu, L.
|
|
|
29 |
6 |
p. 1445-1453
|
artikel
|
| 30 |
The allure of ‘ALUR’
|
Nagasaka, M.
|
|
|
29 |
6 |
p. 1344-1346
|
artikel
|
| 31 |
The hard road to data interpretation: the road is hard too for the patient
|
Gore-Booth, J.
|
|
|
29 |
6 |
p. 1486
|
artikel
|
Tijdschrift beschrijving